Ph 2 Elacestrant in ER Positive Uterine Sarcomas
🩺 Protocol Summary
This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas. The name of the study drug involved in this research study is: -Elacestrant (a type of selective estrogen receptor degrader)
Primary Research Facility: Dana Farber Cancer Institute (Boston, Massachusetts)
📋 Preliminary Self-Screener
0 of 3 AnsweredAnswer all 3 basic criteria below to see your preliminary screening result:
📍 Primary Site Map
Site: Dana Farber Cancer Institute — Boston, Massachusetts
📄 Print Doctor Discussion Sheet
Preview and print a 1-page summary with 5 tailored questions for your physician.
💰 Clinical Trial Costs & Insurance Coverage
Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act § 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.
💡 Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.